CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases
Authors
S Al-Mahdawi
MA Pook
SA Virmouni
Publication date
1 January 2014
Publisher
'Frontiers Media SA'
Doi
View
on
PubMed
Abstract
Copyright © 2014 Al-Mahdawi, Anjomani Virmouni and Pook. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.This article has been made available through the Brunel Open Access Publishing Fund.DNA methylation primarily occurs within human cells as a 5-methylcytosine (5mC) modification of the cytosine bases in CpG dinucleotides. 5mC has proven to be an important epigenetic mark that is involved in the control of gene transcription for processes such as development and differentiation. However, recent studies have identified an alternative modification, 5-hydroxymethylcytosine (5hmC), which is formed by oxidation of 5mC by ten-eleven translocation (TET) enzymes. The overall levels of 5hmC in the mammalian genome are approximately 10% of 5mC levels, although higher levels have been detected in tissues of the central nervous system (CNS). The functions of 5hmC are not yet fully known, but evidence suggests that 5hmC may be both an intermediate product during the removal of 5mC by passive or active demethylation processes and also an epigenetic modification in its own right, regulating chromatin or transcriptional factors involved in processes such as neurodevelopment or environmental stress response. This review highlights our current understanding of the role that 5hmC plays in neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), fragile X-associated tremor/ataxia syndrome (FXTAS), Friedreich ataxia (FRDA), Huntington's disease (HD), and Parkinson's disease (PD).Sara Anjomani Virmouni was supported by funding to Mark A. Pook from the Friedreich’s Ataxia Research Alliance(FARA)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Sustaining member
Brunel University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:bura.brunel.ac.uk:2438/102...
Last time updated on 18/05/2015
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.3389%2Ffnins.2014....
Last time updated on 01/04/2019
Frontiers - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 05/06/2019
Frontiers - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 15/05/2017